Lilly's phase 2 retatrutide results show the investigational molecule achieved up to 17.5% mean weight reduction
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Dr. Reddy's aims to roll out its trade generics across cities and towns in India
GenWorks has scaled up its e-commerce platform in terms of building traffic
This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments
Urges Innovators to produce quality products that can be deployed at scale
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Pfizer is likely to show GSK significant competition
Agreement provides customers in the majority of Europe* access to supply through Univar Solutions distribution network
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable
Subscribe To Our Newsletter & Stay Updated